Clarke CH - Search Results

1

SELDI-TOF-MS proteomics of breast cancer.

Clarke CH, Buckley JA, Fung ET. Clarke CH, et al. Clin Chem Lab Med. 2005;43(12):1314-20. doi: 10.1515/CCLM.2005.225. Clin Chem Lab Med. 2005. PMID: 16309366 Review.

2

Optimized conditions for a quantitative SELDI TOF MS protein assay.

Lomas L, Clarke CH, Thulasiraman V, Fung E. Lomas L, et al. Among authors: clarke ch. Methods Mol Biol. 2012;818:1-10. doi: 10.1007/978-1-61779-418-6_1. Methods Mol Biol. 2012. PMID: 22083812

3

Proteomic biomarkers apolipoprotein A1, truncated transthyretin and connective tissue activating protein III enhance the sensitivity of CA125 for detecting early stage epithelial ovarian cancer.

Clarke CH, Yip C, Badgwell D, Fung ET, Coombes KR, Zhang Z, Lu KH, Bast RC Jr. Clarke CH, et al. Gynecol Oncol. 2011 Sep;122(3):548-53. doi: 10.1016/j.ygyno.2011.06.002. Epub 2011 Jun 25. Gynecol Oncol. 2011. PMID: 21708402 Free PMC article.

4

Reproducibility of SELDI Spectra Across Time and Laboratories.

Diao L, Clarke CH, Coombes KR, Hamilton SR, Roth J, Mao L, Czerniak B, Baggerly KA, Morris JS, Fung ET, Bast RC Jr. Diao L, et al. Among authors: clarke ch. Cancer Inform. 2011 Mar 14;10:45-64. doi: 10.4137/CIN.S6438. Cancer Inform. 2011. PMID: 21552492 Free PMC article.

5

Quality control and peak finding for proteomics data collected from nipple aspirate fluid by surface-enhanced laser desorption and ionization.

Coombes KR, Fritsche HA Jr, Clarke C, Chen JN, Baggerly KA, Morris JS, Xiao LC, Hung MC, Kuerer HM. Coombes KR, et al. Clin Chem. 2003 Oct;49(10):1615-23. doi: 10.1373/49.10.1615. Clin Chem. 2003. PMID: 14500586

6

Significant differences in nipple aspirate fluid protein expression between healthy women and those with breast cancer demonstrated by time-of-flight mass spectrometry.

Pawlik TM, Fritsche H, Coombes KR, Xiao L, Krishnamurthy S, Hunt KK, Pusztai L, Chen JN, Clarke CH, Arun B, Hung MC, Kuerer HM. Pawlik TM, et al. Among authors: clarke ch. Breast Cancer Res Treat. 2005 Jan;89(2):149-57. doi: 10.1007/s10549-004-1710-4. Breast Cancer Res Treat. 2005. PMID: 15692757 Clinical Trial.

7

Validation of a Biomarker Panel and Longitudinal Biomarker Performance for Early Detection of Ovarian Cancer.

Simmons AR, Clarke CH, Badgwell DB, Lu Z, Sokoll LJ, Lu KH, Zhang Z, Bast RC Jr, Skates SJ. Simmons AR, et al. Among authors: clarke ch. Int J Gynecol Cancer. 2016 Jul;26(6):1070-7. doi: 10.1097/IGC.0000000000000737. Int J Gynecol Cancer. 2016. PMID: 27206285 Free PMC article.

8

DIRAS3 regulates the autophagosome initiation complex in dormant ovarian cancer cells.

Lu Z, Baquero MT, Yang H, Yang M, Reger AS, Kim C, Levine DA, Clarke CH, Liao WS, Bast RC Jr. Lu Z, et al. Among authors: clarke ch. Autophagy. 2014 Jun;10(6):1071-92. doi: 10.4161/auto.28577. Autophagy. 2014. PMID: 24879154 Free PMC article.

9

ARHI (DIRAS3) induces autophagy in ovarian cancer cells by downregulating the epidermal growth factor receptor, inhibiting PI3K and Ras/MAP signaling and activating the FOXo3a-mediated induction of Rab7.

Lu Z, Yang H, Sutton MN, Yang M, Clarke CH, Liao WS, Bast RC Jr. Lu Z, et al. Among authors: clarke ch. Cell Death Differ. 2014 Aug;21(8):1275-89. doi: 10.1038/cdd.2014.48. Epub 2014 Apr 25. Cell Death Differ. 2014. PMID: 24769729 Free PMC article.

10

Selective estrogen receptor modulator effects in the rat brain.

Zhou W, Koldzic-Zivanovic N, Clarke CH, de Beun R, Wassermann K, Bury PS, Cunningham KA, Thomas ML. Zhou W, et al. Among authors: clarke ch. Neuroendocrinology. 2002 Jan;75(1):24-33. doi: 10.1159/000048218. Neuroendocrinology. 2002. PMID: 11810032

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

78 results

Search Page